| 
   Class and example  | 
  
   Mechanism of action  | 
  
   Side effects  | 
 
| 
   Biguanide e.g. metformin  | 
  
   · ↓Hepatic glucose production (by glycogenolysis, gluconeogenesis) · ↑Insulin sensitivity  | 
  
   · Diarrhoea · Renal impairment: ↑risk if dehydrated, iodine contrast, other nephrotoxins. · Rare lactic acidosis (inhibit complex 1 of electron transport chain)  | 
 
| 
   Sulfonylurea e.g. gliclazide  | 
  
   · Inhibit K+-ATP channel -> depolarisation -> activate VDCC -> ↑ICF Ca2+ -> exocytosis of insulin vesicles ↑insulin release · Requires functioning pancreas  | 
  
   · Risk hypoglycaemia peri-op · Long-term “burnout”, β-cell failure, insulin dependence ·  | 
 
| 
   Apical SGLT2 inhibitor e.g. dapagliflozin  | 
  
   · ↓Glucose reabsorption -> glycosuria · Limit plasma glucose to 10mM · Weight loss  | 
  
   · UTI · Osmotic diuresis · Occult DKA-like state  | 
 
| 
   a-glucosidase inhibitor e.g. acarbose  | 
  
   · ↓Glucose reabsorption · Weight loss  | 
  
   · Osmotic diarrhoea, abdominal pain  | 
 
| 
   DPP4 inhibitor e.g. sitagliptin  | 
  
   · ↓Breakdown of incretins GLP-1 and GIP · Requires functioning pancreas  | 
  
   · Minimal · Nausea · Cold-like symptoms · Photosensitivity  | 
 
| 
   Thiazolidenedione PPARγ agonists e.g. rosiglitazone  | 
  
   · ↓Insulin resistance  | 
  
   · Weight gain, oedema, hepatitis  | 
 
Feedback welcome at ketaminenightmares@gmail.com